November 13, 2017

MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications

PORTLAND, OR and CAMBRIDGE, MA— November 13, 2017 — MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis System.  MolecularMD has completed validation of the MSI Analysis System for the analysis of multiple tumor types and is now offering the technology as part of a broader portfolio …

September 28, 2017

MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services

PORTLAND, OR and CAMBRIDGE, MA— September 28, 2017 — MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug development programs, has announced a partnership agreement with Indica Labs, a leader in digital pathology imaging tools and services. The collaboration between the companies leverages MolecularMD’s diagnostic clinical testing solutions with Indica Labs’ digital biomarker analysis services to …

June 1, 2017

MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries

PORTLAND, OR and CAMBRIDGE, MA— June 1, 2017 — MolecularMD Corp., a molecular diagnostics company that provides  clinical trial services and development of companion diagnostics for targeted and immunotherapies in oncology, is now recognized as a Certified Service Provider of ArcherDX next-generation sequencing (NGS) panels, adding to MolecularMD’s NGS Advanced Diagnostics service offering. The agreement …

June 27, 2016

MolecularMD Enters Into a Collaboration Agreement with Illumina for Drug-Diagnostic Co-development with Biopharma Drug Programs

PORTLAND, OR and CAMBRIDGE, MA – June 27, 2016 – MolecularMD Corporation announced today that it has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN) that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics in support of biopharma drug development program(s). The agreement dovetails MolecularMD’s companion diagnostic development and FDA submission experience with Illumina’s NGS technology.

June 2, 2016

Definiens and MolecularMD Announce Partnership to Combine IHC Assays with Advanced Digital Pathology and Data Mining

Munich, Germany – June 2, 2016 – Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced a partnership agreement with MolecularMD to combine MolecularMD’s expertise in specialty diagnostic assays with Definiens’ quantitative tissue read-outs. MolecularMD is a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies.

April 25, 2016

MolecularMD has obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial

PORTLAND, OR and CAMBRIDGE, MA – April 25, 2016 – MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has partnered with Daiichi Sankyo, Inc. on their work in developing oncology compounds.

November 3, 2015

MolecularMD Announces Presentations at Upcoming AACR-NCI-EORTC International Conference

PORTLAND, OR and CAMBRIDGE, MA – November 3, 2015 – MolecularMD, Corp., a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies, today announced that its liquid biopsy capability will be highlighted in a presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer …

July 16, 2015

MolecularMD Receives New York State Approval for Next Generation Sequencing Test to Support Clinical Trial Enrollment

PORTLAND, OR and CAMBRIDGE, MA – July 16, 2015 – MolecularMD Corp., a molecular diagnostics company that provides companion diagnostic solutions and supporting clinical trial testing services for targeted cancer therapies, received approval from the New York State Department of Health (NYDOH) for its Next Generation Sequencing (NGS) Notch 1 gene mutation analysis in FFPE tissue and whole blood specimens. The test is intended to support clinical trial enrollment.

April 16, 2015

MolecularMD Announces Presentations at Upcoming American Association for Cancer Research Annual Meeting

PORTLAND, OR and CAMBRIDGE, MA – April 16, 2015 – MolecularMD, Corp., a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies, today announced that its Next Generation Sequencing (NGS) capability will be highlighted in two presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2015 taking place April 18 -22 in Philadelphia, PA.

March 26, 2015

MolecularMD Receives ISO Certification for Design, Development and Production of Molecular Diagnostic Products

PORTLAND, OR and CAMBRIDGE, MA – March 26, 2015 – MolecularMD Corp., a molecular diagnostics company that develops custom companion diagnostics and provides clinical trial testing services for targeted cancer therapies, today announced the recent certification by BSI (British Standards Institution) of its Quality Management System to the requirements of ISO 13485:2003. The ISO 13485 …

December 18, 2014

MolecularMD Cambridge Laboratory Receives CAP Accreditation with Focus on NGS Panels for Clinical Trial Enrollment and NGS Liquid Biopsy Testing

PORTLAND, OR and CAMBRIDGE, MA – December 18, 2014 – MolecularMD, Corp., a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies, today announced that it has received accreditation from the College of American Pathologists (CAP) for its Next Generation Sequencing (NGS) Laboratory in Cambridge, MA. To complement its Portland based RT-PCR and IHC companion diagnostic capabilities, the Cambridge laboratory was established in 2012 as an Advanced Diagnostics Development Laboratory for NGS.

June 12, 2014

MolecularMD Develops Notch1 Next Generation Sequencing Test to Support Clinical Development for OncoMed’s anti-Notch1 antibody, OMP-52M51

PORTLAND, OR and CAMBRIDGE, Mass. – June 12, 2014 – MolecularMD Corp., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, in collaboration with OncoMed Pharmaceuticals, Inc., will present the development and validation of a proprietary Notch1 Next Generation DNA Sequencing (NGS) test at the upcoming 19th European Hematology Association (EHA) Congress.

June 2, 2014

MolecularMD to Adopt Oncomine Cancer Research Panel with Ion Torrent Next-Generation Sequencing Platform

CARLSBAD, Calif. – June 2, 2014– MolecularMD will be validating the Oncomine Cancer Research Panel in their CLIA and FDA 21 CFR part 820 compliant diagnostic testing facility to provide comprehensive genomic tumor profiling to support early and late stage clinical development of molecularly targeted cancer therapies.

April 4, 2014

MolecularMD Receives CLIA Certification for its Second Next Generation Sequencing Laboratory

PORTLAND, OR and CAMBRIDGE, Mass. – April 4, 2014 – MolecularMD Corp., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, today announced certification of its Next Generation Sequencing (NGS) clinical laboratory in Cambridge, Massachusetts under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. The Cambridge lab complements MolecularMD’s Portland, OR CLIA lab and GMP manufacturing facility to provide custom solutions for NGS-based companion diagnostics. The lab was initially established as a development center of excellence for NGS and has now been expanded as a dedicated center for NGS clinical testing under CLIA to support early stage and pivotal clinical studies.

February 19, 2014

MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trial

Portland, OR, February 19, 2014 — MolecularMD Corp. today announced that it has entered into a collaboration with Novartis Pharmaceuticals Corporation to develop a companion diagnostic test to aid in the identification of Ph+ chronic myelogenous leukemia (CML) patients who have achieved durable minimal residual disease (MRD) with nilotinib (Tasigna®), and to provide molecular monitoring for patients during treatment-free remission.